Increasing Prevalence of Epilepsy, Depression, and Migraine to Augment the Vagus Nerve Stimulators Market Growth
Vagus nerve stimulation is a U.S. FDA
approved medical procedure used to deliver electrical impulses to the vagus
nerve for the management and treatment of various diseases such as
irritable bowel syndrome, gastric motility disorder, chronic obstructive
pulmonary disease, exercise-induced bronchospasm, bronchoconstriction, asthma,
migraine, cluster headache, depression, and epilepsy.
It works by delivering
mild electrical impulses to the central nervous system through the vagus nerve.
Vagus nerve stimulation is a non-invasive, non-surgical treatment that has
proven to be effective for many types of patients. At present, two types of
vagus nerve stimulators are available in the market, such as implantable and
external vagus nerve stimulator.
Market Dynamics:
Increasing prevalence of epilepsy, depression, and migraine
is expected to propel the growth of the vagus
nerve stimulators market. Epilepsy is a chronic, non-communicable disease
of the brain that affects people of all ages. According to the World Health
Organization, worldwide, around 50 million people have epilepsy, which makes it
one of the most common neurological diseases worldwide.
Continuous research and development activities by major
players are also expected to fuel the growth of the vagus nerve stimulators
market. For instance, in January 2021, electroCore, Inc. announced that Centers
for Medicare and Medicaid Services published its most recent Level II
Healthcare Common Procedure Coding System decisions, establishing a unique code
K1020 ‘Non-invasive vagus nerve stimulator’.
The emergence of COVID-19 is expected to offer lucrative
growth opportunities for players in the vagus nerve stimulators market. For
instance, in July 2020, the FDA (Food and Drug Administration) granted an
Emergency Use Authorization for the use of the gammaCore Sapphire CV nVNS
therapy at home or in a healthcare setting to treat adult patients with known
or suspected COVID-19.
Competitive Analysis:
Major players operating in the vagus nerve stimulators
market are tVNS Technologies GmbH, Nervana, Parasym Ltd., Beijing PINS Medical
Co., MicroTransponder, SetPoint Medical Corporation, LivaNova, and electroCore.
Major players in the market are involved in different
business strategies, such as product launch. Product approval, etc., to
strengthen their product portfolio. For instance, in October 2020, the FDA
awarded SetPoint Medical breakthrough device designation for a bioelectronic
technology that stimulates the vagus nerve to treat rheumatoid arthritis (RA).
Moreover, in April 2020, FDA approved an expanded indication
for gammaCore (electroCore) to include the prevention of migraine in adult
patients. Whereas, in March 2020, LivaNova announced that its vagus nerve
stimulation therapy system, Symmetry, received CE Mark approval for
Difficult-to-Treat Depression (DTD).

Comments
Post a Comment